These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30315343)

  • 21. The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
    Obama K
    Acta Haematol; 2015; 134(4):229-30. PubMed ID: 26066978
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
    Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
    Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study.
    Knauf W; Tapprich C; Schlag R; Schütz S; Alkemper B; Gaede B; Reschke D; Schmits R; Schwarzer A
    Oncol Res Treat; 2015; 38(4):167-73. PubMed ID: 25877940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyponatremia in a multiple myeloma patient treated with bortezomib.
    Shimazu Y; Fujimura K
    Hematol Oncol; 2017 Dec; 35(4):929-930. PubMed ID: 28004404
    [No Abstract]   [Full Text] [Related]  

  • 25. Neutrophilic dermatosis: disease mechanism and treatment.
    Maalouf D; Battistella M; Bouaziz JD
    Curr Opin Hematol; 2015 Jan; 22(1):23-9. PubMed ID: 25394310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis.
    Surovy AM; Pelivani N; Hegyi I; Buettiker U; Beltraminelli H; Borradori L
    JAMA Dermatol; 2013 Jan; 149(1):79-83. PubMed ID: 23324762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide.
    Hoverson AR; Davis MD; Weenig RH; Wolanskyj AP
    Arch Dermatol; 2006 Aug; 142(8):1070-1. PubMed ID: 16924066
    [No Abstract]   [Full Text] [Related]  

  • 29. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
    J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutrophilic dermatosis caused by azathioprine.
    Valentine MC; Walsh JS
    Skinmed; 2011; 9(6):386-8. PubMed ID: 22256629
    [No Abstract]   [Full Text] [Related]  

  • 32. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
    Keating M; Dasanu CA
    BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
    Geffray L
    Rev Med Interne; 2009 May; 30(5):465-8. PubMed ID: 19349101
    [No Abstract]   [Full Text] [Related]  

  • 38. Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
    Popat R; Maharaj L; Oakervee H; Cavenagh J; Joel S
    Br J Haematol; 2013 Jan; 160(1):111-4. PubMed ID: 23078038
    [No Abstract]   [Full Text] [Related]  

  • 39. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.